Bibliographic record
Abstract
Currently approved ALK inhibitorsThe detection of ALK rearrangement has changed the treatment and prognosis in this subgroup of patients.Crizotinib, which was originally developed for treatment of anaplastic large-cell lymphoma.4 Table 1 was the first ALK inhibitor to be approved by the FDA in November 2014 for treatment of ALK rearranged NSCLC in the second line setting.The approval was based on the results of the PROFILE 1007, with PFS of 7.7 months, compare to 3months in the chemotherapy arm, and the RR was 65%. 5 Crizotinib waslater on approved for the 1st line treatment based on the results of the PROFILE 1014 phase III trial, showing PFS of 10.9 months vs. 7 months, and RR of 74% vs. 45% in the Crizotinib and chemotherapy arm, respectively.6 The toxicity profile of crizotinib is different from chemotherapy, and includes vision disorders, diarrhea, nausea, vomiting, constipation, elevated liver aminotransferase levels and edema (Table 1).Currently, crizotinib is the standard 1st line treatment for NSCLC harboring ALK rearrangement, although most of the patients will develop resistance to treatment after a median of 10 months.Resistance to treatment is uasually related to the emergence of new resistant clones.7 About a quarter of patients with ALK-rearranged NSCLC will have CNS involvement at time of diagnosis, and that site is the most frequent site of disease progression.8 The inevitable resistance to treatment raised the need for new ALK inhibitors, with high penetrance of the bloodbrain barrier and activity against the resistant clones in the second line setting and beyond.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".